With the release of the revised USP <797> guidance, it is important to revisit some of the basics of sterile compounding. The Section of Inpatient Care Practitioner’s SAG on Compounding Practice has developed a three-part series that will cover differing definitions of compounding, beyond use dates (BUDs), and changes from low, medium, and high risk compounding categories. In this third episode of the series, speakers will focus on one of the most significant changes between the currently enforceable version and the upcoming version: the change from low, medium, and high risk to category 1, 2, and 3 compounding and how this impacts BUDs. 
The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.